CD40 and rectum adenocarcinoma: INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer, a Phase II Randomized Multi-center Trial of Neoadjuvant Therapy With and Without APX005M, an Anti-CD40 Agonist, APX005M, for Locally Advanced Rectal Adenocarcinoma